|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.11.25 - 22:36
|
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results (Business Wire)
|
|
|
US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter
937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE)
Launched EKTERLY in Germany with initial orders signaling encouraging demand
$309M in cash expected to fund the Company through profitability
Management to host conference call Tuesday, November 11th at 8:30 a.m. ETFRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025.
“The US launch of EKTERLY is progressing with significant momentum, driven by strong early demand and rapid adoption among physicians and people living with HAE. We continue to see encouraging trends, with both new patient starts and repeat prescriptions increasing consistently, reflecting sustained uptake and confidenc...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
